PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.

ABSTRACT:

Introduction

Hotspots (HS) mutations in the PIK3CA gene may lead to poorer oncological outcomes and endocrine resistance in advanced breast cancer (BC), but their prognostic role in early-stage disease remains controversial. The overall agreement within plasma and tissue methods has not been well explored. Our aim was to correlate tissue and plasma approaches and to analyze the prognostic impact of PIK3CA mutations (PIK3CAm) in HR+/HER2- BC.

Methods

A retrospective and unicentric analysis of PIK3CA mutational status in tissue and plasma samples by Cobas®PIK3CA Mutation Kit in patients with HR+/HER2- BC.

Results

We analyzed 225 samples from 161 patients with luminal BC. PIK3CA mutations were identified in 62 patients (38.5%), of which 39.6% were found in tissue and 11.

SUBMITTER: Teran E 

PROVIDER: S-EPMC11375731 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature